Mitchell Machtay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mitchell Machtay has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- David I. Rosenthal
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
6 shared publications Ara A. Chalian
Department of Otorhinolaryngology—Head and Neck Surgery, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, U.S.A.
3 shared publicationsGregory S. Weinstein
From the Department of Radiation Oncology, Division of Medical Oncology, Department of Medicine, and Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania Medical Center, Philadelphia, and Pocono Medical Center, East Stroudsburg, PA; and Department of Medical Oncology, Falmouth Hospital Oncology Center, Mashpee, MA
3 shared publicationsJason H. Lee
From the Departments of Radiation Oncology and Thoracic Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA
3 shared publicationsRandal S. Weber
From the Department of Radiation Oncology, Division of Medical Oncology, Department of Medicine, and Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania Medical Center, Philadelphia, and Pocono Medical Center, East Stroudsburg, PA; and Department of Medical Oncology, Falmouth Hospital Oncology Center, Mashpee, MA
3 shared publicationsLarry R. Kaiser
From the Departments of Radiation Oncology and Thoracic Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA
2 shared publications
Latest Publications
- 1 October 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 96 (2) , S116-S117
Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy in Head and Neck Squamous Cell Carcinoma: A Pooled Analysis of NRG Oncology/RTOG 0129 and 0522
- 1 October 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 96 (2) , S116-S117
Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy in Head and Neck Squamous Cell Carcinoma: A Pooled Analysis of NRG Oncology/RTOG 0129 and 0522
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 7571
Pilot study of carboplatin/radiotherapy plus ‘dose-dense’ pemetrexed for locally advanced non-small cell lung carcinoma
7571 Background: This is a prospective Pilot/Phase I dose-seeking clinical trial of dose-dense (q2-week) pemetrexed given concurrently with radiotherapy (XRT) and carboplatin for locally advanced non-small cell lung carcinoma (NSCLC). Methods: Eligible patients had Stage III or IV (oligometastatic) NSCLC. Patients received XRT to 63 Gy (conventional fractionation) with carboplatin (AUC = 6) during Weeks 1 and 5 of XRT, and pemetrexed during Weeks 1, 3, 5, and 7 of XRT. Vitamin prophylaxis (B12/folate) was started prior to treatment. The starting dose level of pemetrexed was 300 mg/m2, with plans to dose escalate after 3–6 patients had at least 30 days of evaluability post-treatment without dose-limiting toxicity (DLT). DLT was defined as any Grade 4 toxicity, selected Grade 3 toxicities (chemo-XRT pneumonopathy, esophagitis lasting > 14 days), and/or inability to complete at least 54 Gy of XRT). Consolidation carboplatin (AUC=6) and pemetrexed (500 mg/m2) q3 weeks × 2 cycles was also planned. Results: Fourteen patients were enrolled; 10 are evaluable for feasibility/toxicity; 9 are evaluable for response. All 10 patients received both doses of concurrent carboplatin; 9/10 received a full dose of XRT. Five of 10 patients received four doses of pemetrexed; the median cumulative concurrent pemetrexed dose delivered was 1,150 mg/m2. The main toxicity of concurrent chemo-XRT was neutropenia, with a median ANC nadir of 1.4; three patients had Grade ≥ 3 neutropenia. One patient had multiple Grade 4 toxicities (infection, multi-organ failure) and a 2nd patient had prolonged Grade 3 esophagitis - these were considered DLTs and the study was amended to require reduced XRT field size (involved field). No patient had Grade ≥3 chemo-XRT pneumonopathy. All patients recovered from their acute toxicities; there were no treatment-related deaths and no unusual/unexpected toxicities. In-field local tumor responses were observed in 7 of 9 evaluable patients. Conclusions: Although generally well tolerated, feasible and active, XRT/pemetrexed/carboplatin as given in the original design of Dose Level I exceeded pre-defined DLT boundaries. Study accrual continues, using involved field XRT, and updated data will be presented.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 7571
Pilot study of carboplatin/radiotherapy plus ‘dose-dense’ pemetrexed for locally advanced non-small cell lung carcinoma
7571 Background: This is a prospective Pilot/Phase I dose-seeking clinical trial of dose-dense (q2-week) pemetrexed given concurrently with radiotherapy (XRT) and carboplatin for locally advanced non-small cell lung carcinoma (NSCLC). Methods: Eligible patients had Stage III or IV (oligometastatic) NSCLC. Patients received XRT to 63 Gy (conventional fractionation) with carboplatin (AUC = 6) during Weeks 1 and 5 of XRT, and pemetrexed during Weeks 1, 3, 5, and 7 of XRT. Vitamin prophylaxis (B12/folate) was started prior to treatment. The starting dose level of pemetrexed was 300 mg/m2, with plans to dose escalate after 3–6 patients had at least 30 days of evaluability post-treatment without dose-limiting toxicity (DLT). DLT was defined as any Grade 4 toxicity, selected Grade 3 toxicities (chemo-XRT pneumonopathy, esophagitis lasting > 14 days), and/or inability to complete at least 54 Gy of XRT). Consolidation carboplatin (AUC=6) and pemetrexed (500 mg/m2) q3 weeks × 2 cycles was also planned. Results: Fourteen patients were enrolled; 10 are evaluable for feasibility/toxicity; 9 are evaluable for response. All 10 patients received both doses of concurrent carboplatin; 9/10 received a full dose of XRT. Five of 10 patients received four doses of pemetrexed; the median cumulative concurrent pemetrexed dose delivered was 1,150 mg/m2. The main toxicity of concurrent chemo-XRT was neutropenia, with a median ANC nadir of 1.4; three patients had Grade ≥ 3 neutropenia. One patient had multiple Grade 4 toxicities (infection, multi-organ failure) and a 2nd patient had prolonged Grade 3 esophagitis - these were considered DLTs and the study was amended to require reduced XRT field size (involved field). No patient had Grade ≥3 chemo-XRT pneumonopathy. All patients recovered from their acute toxicities; there were no treatment-related deaths and no unusual/unexpected toxicities. In-field local tumor responses were observed in 7 of 9 evaluable patients. Conclusions: Although generally well tolerated, feasible and active, XRT/pemetrexed/carboplatin as given in the original design of Dose Level I exceeded pre-defined DLT boundaries. Study accrual continues, using involved field XRT, and updated data will be presented.
- 18 September 2003
- Published by Wiley in Seminars in Surgical Oncology
- Vol. 21 (2) , 128-137
Complex and controversial issues in locally advanced non-small cell lung carcinoma
Locally advanced non-small cell lung carcinoma (NSCLC) presents enormous challenges to clinicians and researchers. Because of the absence of metastatic disease, it is a potentially curable condition, greatly differentiating it from stage IV NSCLC. The median and actuarial survival rates are poor, though clearly improved in the past decade, and clearly better than several other types of locally advanced malignancies (e.g., pancreatic cancer, glioblastoma). As demonstrated in Table I, the combination of chemotherapy and radiotherapy has earned the designation of "standard of care" for most good-performance-status patients with locally advanced NSCLC. It is likely that improvements in radiotherapy have also contributed to the enhanced survival and local control rates in this disease. With concurrent chemoradiotherapy, the majority of patients can receive a substantial local response (Fig. 1). Many achieve durable local control, only to succumb to eventual distant metastatic failure. There remains much room for improvement, and there are several avenues for clinical and translational research that offer promise. These include new systemic chemotherapy options (and newer ways of combining these drugs with radiotherapy), improvements in radiotherapy fractionation and dose intensity, methods of protection from chemoradiotherapy toxicity, specific therapies to prevent brain metastatic failure, and the integration of biologically targeted molecules into chemoradiation programs. This article summarizes the advances in the treatment of locally advanced NSCLC over the past several decades and explores some of the many remaining controversies and areas for future investigation.
- 18 September 2003
- Published by Wiley in Seminars in Surgical Oncology
- Vol. 21 (2) , 128-137
Complex and controversial issues in locally advanced non-small cell lung carcinoma
Locally advanced non-small cell lung carcinoma (NSCLC) presents enormous challenges to clinicians and researchers. Because of the absence of metastatic disease, it is a potentially curable condition, greatly differentiating it from stage IV NSCLC. The median and actuarial survival rates are poor, though clearly improved in the past decade, and clearly better than several other types of locally advanced malignancies (e.g., pancreatic cancer, glioblastoma). As demonstrated in Table I, the combination of chemotherapy and radiotherapy has earned the designation of "standard of care" for most good-performance-status patients with locally advanced NSCLC. It is likely that improvements in radiotherapy have also contributed to the enhanced survival and local control rates in this disease. With concurrent chemoradiotherapy, the majority of patients can receive a substantial local response (Fig. 1). Many achieve durable local control, only to succumb to eventual distant metastatic failure. There remains much room for improvement, and there are several avenues for clinical and translational research that offer promise. These include new systemic chemotherapy options (and newer ways of combining these drugs with radiotherapy), improvements in radiotherapy fractionation and dose intensity, methods of protection from chemoradiotherapy toxicity, specific therapies to prevent brain metastatic failure, and the integration of biologically targeted molecules into chemoradiation programs. This article summarizes the advances in the treatment of locally advanced NSCLC over the past several decades and explores some of the many remaining controversies and areas for future investigation.
- 1 October 2002
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (19) , 3964-3971
Organ Preservation Therapy Using Induction Plus Concurrent Chemoradiation for Advanced Resectable Oropharyngeal Carcinoma: A University of Pennsylvania Phase II Trial
PURPOSE: To determine the efficacy, feasibility, and toxicity of a new regimen for locally advanced oropharyngeal carcinoma. PATIENTS AND METHODS: Patients had technically resectable stage III/IV squamous cell carcinoma of the oropharynx, exclusive of T1-2N1. Induction chemotherapy consisted of carboplatin (area under the curve formula equal to 6) and paclitaxel 200 mg/m2 for two cycles, followed by re-evaluation. Patients with major response continued to definitive radiotherapy (70 Gy over 7 weeks) plus concurrent once-weekly paclitaxel (30 mg/m2/wk). Patients with advanced neck disease also underwent post–radiation therapy neck dissection and two more chemotherapy cycles. RESULTS: Fifty-three patients were enrolled. Median follow-up was 31 months (minimum follow-up for survivors was 18 months). The major response rate to induction chemotherapy was 89%; 90% of patients had a complete response after concurrent chemoradiation. Actuarial survival at 3 years was 70%, and 3-year event-free survival was 59%. The 3-year actuarial locoregional control was 82% and the 3-year actuarial rate of distant metastases was 19%. Organ preservation was achieved in 77% of all patients. One patient (2%) died during therapy. Late grade 3 toxicity occurred in 24% of patients, consisting mainly of chronic dysphagia/aspiration and/or radiation soft tissue ulceration. The treatment-related mortality rate was 4% (two patients died from respiratory failure). CONCLUSION: Response to induction chemotherapy as studied in this trial was not useful as a predictive marker for ultimate outcome or organ conservation. Overall, however, this regimen offers good disease control and survival for patients with locally advanced oropharyngeal carcinoma, comparable with other concurrent chemoradiation programs. Further study of similar protocols is indicated.
- 1 October 2002
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (19) , 3964-3971
Organ Preservation Therapy Using Induction Plus Concurrent Chemoradiation for Advanced Resectable Oropharyngeal Carcinoma: A University of Pennsylvania Phase II Trial
PURPOSE: To determine the efficacy, feasibility, and toxicity of a new regimen for locally advanced oropharyngeal carcinoma. PATIENTS AND METHODS: Patients had technically resectable stage III/IV squamous cell carcinoma of the oropharynx, exclusive of T1-2N1. Induction chemotherapy consisted of carboplatin (area under the curve formula equal to 6) and paclitaxel 200 mg/m2 for two cycles, followed by re-evaluation. Patients with major response continued to definitive radiotherapy (70 Gy over 7 weeks) plus concurrent once-weekly paclitaxel (30 mg/m2/wk). Patients with advanced neck disease also underwent post–radiation therapy neck dissection and two more chemotherapy cycles. RESULTS: Fifty-three patients were enrolled. Median follow-up was 31 months (minimum follow-up for survivors was 18 months). The major response rate to induction chemotherapy was 89%; 90% of patients had a complete response after concurrent chemoradiation. Actuarial survival at 3 years was 70%, and 3-year event-free survival was 59%. The 3-year actuarial locoregional control was 82% and the 3-year actuarial rate of distant metastases was 19%. Organ preservation was achieved in 77% of all patients. One patient (2%) died during therapy. Late grade 3 toxicity occurred in 24% of patients, consisting mainly of chronic dysphagia/aspiration and/or radiation soft tissue ulceration. The treatment-related mortality rate was 4% (two patients died from respiratory failure). CONCLUSION: Response to induction chemotherapy as studied in this trial was not useful as a predictive marker for ultimate outcome or organ conservation. Overall, however, this regimen offers good disease control and survival for patients with locally advanced oropharyngeal carcinoma, comparable with other concurrent chemoradiation programs. Further study of similar protocols is indicated.
- 1 October 2002
- Published by Wiley in The Laryngoscope
- Vol. 112 (10) , 1883-1887
Relative Risk of Stroke in Head and Neck Carcinoma Patients Treated With External Cervical Irradiation
Objective To determine the rate of cerebrovascular events (stroke) in patients irradiated to high doses for squamous cell carcinoma of the head and neck.Study Design Retrospective chart review of 413 patients treated from 1987 to 2000 with squamous cell carcinoma of the head and neck was performed to determine the risk of stroke compared with the expected rate.Methods Surgical, radiotherapeutic, radiological, and clinical or office records of 413 patients were analyzed, and data were collected regarding clinical risk factors for stroke, irradiation parameters, and follow‐up on whether or not a stroke event occurred. The actuarial risk of stroke for this population was calculated and compared with expected risk from population‐based data.Results Of the 413 patients, 20 had strokes in follow‐up, occurring between 2 and 146 months after radiotherapy. The 5‐year actuarial rate of stroke was 12%, which corresponded to a relative risk of 2.09 (P = .0007) compared with the population‐based “expected” data. Median radiation therapy dose was 64 Gy; there was no correlation between radiation therapy dose and stroke risk. No correlation was identified between surgery near the carotids and stroke risk.Conclusions An association between high‐dose cervical irradiation for squamous cell carcinoma of the head and neck and stroke is demonstrated. Although the relative risk is approximately doubled, the absolute risk is modest in comparison to the risk of cancer recurrence. Further study of this association and possible interventions is warranted.
- 1 October 2002
- Published by Wiley in The Laryngoscope
- Vol. 112 (10) , 1883-1887
Relative Risk of Stroke in Head and Neck Carcinoma Patients Treated With External Cervical Irradiation
Objective To determine the rate of cerebrovascular events (stroke) in patients irradiated to high doses for squamous cell carcinoma of the head and neck.Study Design Retrospective chart review of 413 patients treated from 1987 to 2000 with squamous cell carcinoma of the head and neck was performed to determine the risk of stroke compared with the expected rate.Methods Surgical, radiotherapeutic, radiological, and clinical or office records of 413 patients were analyzed, and data were collected regarding clinical risk factors for stroke, irradiation parameters, and follow‐up on whether or not a stroke event occurred. The actuarial risk of stroke for this population was calculated and compared with expected risk from population‐based data.Results Of the 413 patients, 20 had strokes in follow‐up, occurring between 2 and 146 months after radiotherapy. The 5‐year actuarial rate of stroke was 12%, which corresponded to a relative risk of 2.09 (P = .0007) compared with the population‐based “expected” data. Median radiation therapy dose was 64 Gy; there was no correlation between radiation therapy dose and stroke risk. No correlation was identified between surgery near the carotids and stroke risk.Conclusions An association between high‐dose cervical irradiation for squamous cell carcinoma of the head and neck and stroke is demonstrated. Although the relative risk is approximately doubled, the absolute risk is modest in comparison to the risk of cancer recurrence. Further study of this association and possible interventions is warranted.
- 1 October 2001
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (19) , 3912-3917
Risk of Death From Intercurrent Disease Is Not Excessively Increased by Modern Postoperative Radiotherapy for High-Risk Resected Non–Small-Cell Lung Carcinoma
PURPOSE: Some studies report a high risk of death from intercurrent disease (DID) after postoperative radiotherapy (XRT) for non–small-cell lung cancer (NSCLC). This study determines the risk of DID after modern-technique postoperative XRT. PATIENTS AND METHODS: A total of 202 patients were treated with surgery and postoperative XRT for NSCLC. Most patients (97%) had pathologic stage II or III disease. Many patients (41%) had positive/close/uncertain resection margins. The median XRT dose was 55 Gy with fraction size of 1.8 to 2 Gy. The risk of DID was calculated actuarially and included patients who died of unknown/uncertain causes. Median follow-up was 24 months for all patients and 62 months for survivors. RESULTS: A total of 25 patients (12.5%) died from intercurrent disease, 16 from confirmed noncancer causes and nine from unknown causes. The 4-year actuarial rate of DID was 13.5%. This is minimally increased compared with the expected rate for a matched population (approximately 10% at 4 years). On multivariate analysis, age and radiotherapy dose were borderline significant factors associated with a higher risk of DID (P = .06). The crude risk of DID for patients receiving less than 54 Gy was 2% (4-year actuarial risk 0%) versus 17% for XRT dose ≥ 54 Gy. The 4-year actuarial overall survival was 34%; local control was 84%; and freedom from distant metastases was 37%. CONCLUSION: Modern postoperative XRT for NSCLC does not excessively increase the risk of intercurrent deaths. Further study of postoperative XRT, particularly when using more sophisticated treatment planning and reasonable total doses, for carefully selected high-risk resected NSCLC is warranted.
- 1 October 2001
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (19) , 3912-3917
Risk of Death From Intercurrent Disease Is Not Excessively Increased by Modern Postoperative Radiotherapy for High-Risk Resected Non–Small-Cell Lung Carcinoma
PURPOSE: Some studies report a high risk of death from intercurrent disease (DID) after postoperative radiotherapy (XRT) for non–small-cell lung cancer (NSCLC). This study determines the risk of DID after modern-technique postoperative XRT. PATIENTS AND METHODS: A total of 202 patients were treated with surgery and postoperative XRT for NSCLC. Most patients (97%) had pathologic stage II or III disease. Many patients (41%) had positive/close/uncertain resection margins. The median XRT dose was 55 Gy with fraction size of 1.8 to 2 Gy. The risk of DID was calculated actuarially and included patients who died of unknown/uncertain causes. Median follow-up was 24 months for all patients and 62 months for survivors. RESULTS: A total of 25 patients (12.5%) died from intercurrent disease, 16 from confirmed noncancer causes and nine from unknown causes. The 4-year actuarial rate of DID was 13.5%. This is minimally increased compared with the expected rate for a matched population (approximately 10% at 4 years). On multivariate analysis, age and radiotherapy dose were borderline significant factors associated with a higher risk of DID (P = .06). The crude risk of DID for patients receiving less than 54 Gy was 2% (4-year actuarial risk 0%) versus 17% for XRT dose ≥ 54 Gy. The 4-year actuarial overall survival was 34%; local control was 84%; and freedom from distant metastases was 37%. CONCLUSION: Modern postoperative XRT for NSCLC does not excessively increase the risk of intercurrent deaths. Further study of postoperative XRT, particularly when using more sophisticated treatment planning and reasonable total doses, for carefully selected high-risk resected NSCLC is warranted.
- 1 December 1999
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 213 (3) , 845-852
Non-Small Cell Lung Cancer: Prognostic Factors in Patients Treated with Surgery and Postoperative Radiation Therapy
PURPOSE: To determine survival outcomes, to identify adverse prognostic factors for relapse, and to compare American Joint Commission on Cancer (AJCC) staging systems in patients with non–small cell lung cancer (NSCLC) treated with surgery and postoperative radiation therapy. MATERIALS AND METHODS: Between 1980 and 1995, 211 patients with NSCLC underwent surgery and postoperative radiation therapy. Surgery consisted of wedge resection (12.5%), lobectomy (67.8%), or pneumonectomy (19.7%). Pathologic stages (1992 AJCC) included I (n = 22), II (n = 70), IIIA (n = 104), and IIIB (n = 12). Indications for radiation therapy included compromised margins (n = 81) and/or positive mediastinal nodes (n = 55). Prognostic factors were identified by using univariate and multivariate models. RESULTS: Overall 3-year survival for patients with stage I, II, and IIIA cancer was 58.9%, 44.1%, and 43.2%, respectively. Older age (P = .008), male sex (P = .021), large primary tumor (P = .004), and multiple positive mediastinal ...
- 1 December 1999
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 213 (3) , 845-852
Non-Small Cell Lung Cancer: Prognostic Factors in Patients Treated with Surgery and Postoperative Radiation Therapy
PURPOSE: To determine survival outcomes, to identify adverse prognostic factors for relapse, and to compare American Joint Commission on Cancer (AJCC) staging systems in patients with non–small cell lung cancer (NSCLC) treated with surgery and postoperative radiation therapy. MATERIALS AND METHODS: Between 1980 and 1995, 211 patients with NSCLC underwent surgery and postoperative radiation therapy. Surgery consisted of wedge resection (12.5%), lobectomy (67.8%), or pneumonectomy (19.7%). Pathologic stages (1992 AJCC) included I (n = 22), II (n = 70), IIIA (n = 104), and IIIB (n = 12). Indications for radiation therapy included compromised margins (n = 81) and/or positive mediastinal nodes (n = 55). Prognostic factors were identified by using univariate and multivariate models. RESULTS: Overall 3-year survival for patients with stage I, II, and IIIA cancer was 58.9%, 44.1%, and 43.2%, respectively. Older age (P = .008), male sex (P = .021), large primary tumor (P = .004), and multiple positive mediastinal ...
- Open Access
- 1 May 1999
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 44 (2) , 311-315
A phase I trial of 96-hour padlitaxel infusion plus accelerated radiotherapy of unrespectable head and neck cancer
- 1 May 1999
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 44 (2) , 311-315
Open AccessA phase I trial of 96-hour padlitaxel infusion plus accelerated radiotherapy of unrespectable head and neck cancer
- 1 April 1999
- Vol. 9, 97-101
Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers.
The goal of these National Cancer Institute-sponsored phase I trials is to determine the feasibility, toxicity, and pharmacokinetics of continuous-infusion (24 hr/d, 7 d/wk, 7 weeks total) intravenous paclitaxel combined with standard, curative-intent thoracic radiation therapy (XRT) for previously untreated, locally advanced non-small cell lung cancer and squamous cell cancer of the head and neck (HNSCC). Eligible patients have locally advanced (T4NXM0 or TXN2-3M0) non-small cell lung cancer ineligible for potentially curative surgical resection or locally advanced HNSCC with an expected 5-year survival rate of less than 25%, as well as a good performance status, adequate hematologic, hepatic, and renal function, and no distant metastases. Non-small cell lung cancer patients receive a total tumor dose of 64.8 Gy megavoltage XRT in 7 weeks at 1.8 Gy once daily, 5 d/wk. Patients with HNSCC receive 70 Gy megavoltage XRT in 7 weeks at 2 Gy once daily, 5 d/wk. Paclitaxel is delivered by continuous intravenous infusion starting 48 hours before XRT and continuing for its duration. The dose of paclitaxel is escalated in cohorts of three patients in a standard phase I design. To date, 49 patients have been entered on both studies and 43 are evaluable for toxicity. Paclitaxel dose is currently at the 17 mg/m2/d dose level, with no dose-limiting toxicity thus far. Clinical outcomes suggest significant activity for this combination. This therapy is feasible and has been well-tolerated through current dose levels. Dose escalation is ongoing.
- 1 April 1999
- Vol. 9, 97-101
Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers.
The goal of these National Cancer Institute-sponsored phase I trials is to determine the feasibility, toxicity, and pharmacokinetics of continuous-infusion (24 hr/d, 7 d/wk, 7 weeks total) intravenous paclitaxel combined with standard, curative-intent thoracic radiation therapy (XRT) for previously untreated, locally advanced non-small cell lung cancer and squamous cell cancer of the head and neck (HNSCC). Eligible patients have locally advanced (T4NXM0 or TXN2-3M0) non-small cell lung cancer ineligible for potentially curative surgical resection or locally advanced HNSCC with an expected 5-year survival rate of less than 25%, as well as a good performance status, adequate hematologic, hepatic, and renal function, and no distant metastases. Non-small cell lung cancer patients receive a total tumor dose of 64.8 Gy megavoltage XRT in 7 weeks at 1.8 Gy once daily, 5 d/wk. Patients with HNSCC receive 70 Gy megavoltage XRT in 7 weeks at 2 Gy once daily, 5 d/wk. Paclitaxel is delivered by continuous intravenous infusion starting 48 hours before XRT and continuing for its duration. The dose of paclitaxel is escalated in cohorts of three patients in a standard phase I design. To date, 49 patients have been entered on both studies and 43 are evaluable for toxicity. Paclitaxel dose is currently at the 17 mg/m2/d dose level, with no dose-limiting toxicity thus far. Clinical outcomes suggest significant activity for this combination. This therapy is feasible and has been well-tolerated through current dose levels. Dose escalation is ongoing.